Kinase inhibitors’ effects on innate immunity in solid cancers

Chunying Peng, Katrin Rabold, Willem J.M. Mulder, Martin Jaeger, Romana T. Netea-Maier

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Innate immune cells constitute a plastic and heterogeneous cell population of the tumor microenvironment. Because of their high tumor infiltration and close interaction with resident tumor cells, they are compelling targets for anti-cancer therapy through either ablation or functionally reprogramming. Kinase inhibitors (KIs) that target aberrant signaling pathways in tumor proliferation and angiogenesis have been shown to have additional immunological effects on myeloid cells that may contribute to a protective antitumor immune response. However, in patients with malig-nancies, these effects are poorly described, warranting meticulous research to identify KIs’ optimal immunomodulatory effect to support developing targeted and more effective immunotherapy. As many of these KIs are currently in clinical trials awaiting approval for the treatment of several types of solid cancer, we evaluate here the information on this drug class’s immunological effects and how such mechanisms can be harnessed to improve combined treatment regimens in cancer.

Original languageEnglish
Article number5695
JournalCancers
Volume13
Issue number22
DOIs
StatePublished - 1 Nov 2021
Externally publishedYes

Keywords

  • Immune checkpoint inhibitors
  • Immunogenic cell death
  • Kinase inhibitors
  • MDSCs
  • Pyroptosis
  • Tumor microenvironment
  • Tumor-associated macrophages
  • VEGFR

Fingerprint

Dive into the research topics of 'Kinase inhibitors’ effects on innate immunity in solid cancers'. Together they form a unique fingerprint.

Cite this